Teprotumumab (TEPEZZA®), a monoclonal antibody that inhibits the insulin-like growth
factor 1 receptor (IGF-1R), is the first disease-modifying therapy approved for the treatment …

Purpose: Dysthyroid optic neuropathy (DON) is a sight-threatening complication of thyroid
eye disease (TED). This review provides an overview of the epidemiology, pathogenesis …

Efficacy of teprotumumab therapy in patients with long-durat... : Current Opinion in
Ophthalmology Efficacy of teprotumumab therapy in patients with long-duration thyroid eye …

Purpose: Review the historical context of research and changing therapeutic landscape of
thyroid-associated ophthalmopathy (TAO) by focusing on the relationship between TAO …

In this study, we conducted a meta‐analysis to assess the efficacy and safety of
teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed …

A 60-year-old man had a 2-week history of daily recurrent episodes of transient, painless
vision loss, each lasting 3–5 s. He had attended ophthalmology for years because of …

Graves' ophthalmopathy (GO) is an autoimmune disease characterized by lymphocytic
infiltration behind the eyes. The pathogenesis of this disease is complex, and although no …

Literature Commentary : Journal of Neuro-Ophthalmology Literature Commentary : Journal
of Neuro-Ophthalmology Log in or Register Subscribe to journalSubscribe Get new issue …